Document is current
Any future updates will be listed below
-
Authors
Tellier, Julie http://orcid.org/0000-0003-2787-8174
Tarasova, Ilariya http://orcid.org/0000-0002-0895-9385
Nie, Junli
Smillie, Christopher S.
Fedele, Pasquale L.
Cao, Wang H. J. http://orcid.org/0000-0001-8023-6096
Groom, Joanna R. http://orcid.org/0000-0001-5251-7835
Belz, Gabrielle T. http://orcid.org/0000-0002-9660-9587
Bhattacharya, Deepta http://orcid.org/0000-0001-8377-7699
Smyth, Gordon K. http://orcid.org/0000-0001-9221-2892
Nutt, Stephen L. http://orcid.org/0000-0002-0020-6637
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1155342, 1160830, 1058892)
Cancer Council Victoria (N/A, N/A)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R24072073, R24072073)
- License Information
-
More Information
Article History
Received: 25 April 2023
Accepted: 13 November 2023
First Online: 3 January 2024
Competing interests
: Sana Biotechnology has licensed the intellectual property of D.B. and Washington University in St. Louis. Gilead Sciences has licensed the intellectual property of D.B. and Stanford University. D.B. is a cofounder of Clade Therapeutics. D.B. served on an advisory panel for GlaxoSmithKline. The other authors declare no competing interests.
